Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 0/1 Study of the Safety and Tolerability of 177Lu-RAD204, a Lutetium-177 Radiolabelled Single Domain Antibody Against Programmed Cell Death-Ligand 1 in Patients With Metastatic Solid Tumours

NCT06305962 is registered in ClinicalTrials.gov with Radiopharm Theranostics, Ltd as lead sponsor.

NCT NCT06305962
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06305962 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 0/1 Study of the Safety and Tolerability of 177Lu-RAD204, a Lutetium-177 Radiolabelled Single Domain Antibody Against Programmed Cell Death-Ligand 1 in Patients With Metastatic Solid Tumours
Lead sponsor
Radiopharm Theranostics, Ltd
Phase
Phase 1
Overall status
Recruiting
Start date
June 3, 2024
Completion date
December 31, 2027
Enrollment
30 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

cutaneous melanoma, endometrial cancer, hnscc, mmr deficiency, msi-high, non small cell lung cancer, pdl1 gene mutation, small cell lung cancer ( sclc ), tnbc, triple negative breast cancer